HALO Halozyme Therapeutics Inc.

-0.30  -2%
Previous Close 16.72
Open 16.75
Price To book 40.05
Market Cap 2330249390
Shares 141,915,310
Volume 2,354,359
Short Ratio 27.18
Av. Daily Volume 1,220,178

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 open label trial initiation announced July 13, 2017.
PEGPH20 and atezolizumab
Pancreatic cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Phase 1/2 enrollment closed due to lack of efficacy.
Pancreatic and gastric cancers
Phase 1/2 initiated July 2016
Eribulin In Combination With PEGPH20
High-Hyaluronan (HA) HER2-negative breast cancer
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 dosing initiated March 2016. Phase 2 data released January 5, 2017. Oral presentation of Phase 2 data at ASCO June 4, 2017 showed ORR of 45%.
Pancreatic cancer
Phase 1b enrolment resumed July 2016 under revised protocol. Response rate data possible by end of 2017.
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
Approved September 12, 2014.
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 2 topline data released 1Q 2014

Latest News

  1. Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
  2. [$$] Charting the Market
  3. Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE
  4. Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2%
  5. Today's Research Reports on Stocks to Watch: Halozyme Therapeutics and Array Biopharma
  6. Stocks To Watch: Halozyme Therapeutics Sees Relative Strength Rating Rise To 90
  7. Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today
  8. This Small Cap Biotech Soars On Deals With Bristol-Myers, Roche
  9. Halozyme to license drug delivery tech to Bristol-Myers a...
  10. Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
  11. Halozyme Therapeutics Wins Big on Roche License Agreement
  12. Halozyme to license drug delivery tech to Roche, Bristol-Myers
  13. Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
  14. Halozyme's stock soars after Bristol-Myers license deal
  15. Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
  16. Halozyme Increases 2017 Financial Guidance
  17. Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers
  18. Bristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology
  19. See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
  20. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : September 1, 2017

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014873
  2. 8-K - Current report 171014793
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17983777
  4. 8-K - Current report 17947966
  5. 8-K - Current report 17858809
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17858740
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17854922
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826759
  9. 8-K - Current report 17826690
  10. 8-K - Current report 17826488